Vx-864    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
231Alpha-1-antitrypsin deficiency4

231. Alpha-1-antitrypsin deficiency    [ 83 clinical trials,   89 drugs,   (DrugBank: 16 drugs),   35 drug target genes,   46 drug target pathways]
Searched query = "Alpha-1-antitrypsin deficiency", "AATD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 83 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-004881-16-IE
(EUCTR)
29/10/202009/07/2020Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ GenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-864 in PiZZ Subjects Alpha 1 antitrypsin deficiency in Subjects With the PiZZ Genotype
MedDRA version: 23.0;Level: PT;Classification code 10083869;Term: Alpha-1 antitrypsin deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Product Name: VX864
Product Code: VX864
INN or Proposed INN: VX864
Other descriptive name: VX-864
Product Name: VX864
Product Code: VX864
INN or Proposed INN: VX864
Other descriptive name: VX-864
Product Name: VX864
Product Code: VX864
INN or Proposed INN: VX864
Other descriptive name: VX-864
Vertex Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2United States;Canada;Ireland;Netherlands;Germany;United Kingdom;Sweden
2EUCTR2019-004881-16-DE
(EUCTR)
17/09/202010/07/2020Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ GenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-864 in PiZZ Subjects Alpha 1 antitrypsin deficiency in Subjects With the PiZZ Genotype
MedDRA version: 23.0;Level: PT;Classification code 10083869;Term: Alpha-1 antitrypsin deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Product Name: VX864
Product Code: VX864
INN or Proposed INN: VX864
Other descriptive name: VX-864
Product Name: VX864
Product Code: VX864
INN or Proposed INN: VX864
Other descriptive name: VX-864
Vertex Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2United States;Canada;Ireland;Netherlands;Germany;United Kingdom;Sweden
3EUCTR2019-004881-16-GB
(EUCTR)
14/09/202021/07/2020Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ GenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-864 in PiZZ Subjects - VX19-864-101 Efficacy and Safety of VX-864 Alpha 1 antitrypsin deficiency in Subjects With the PiZZ Genotype
MedDRA version: 23.0;Level: PT;Classification code 10083869;Term: Alpha-1 antitrypsin deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Product Name: VX864
Product Code: VX864
Other descriptive name: VX-864
Product Name: VX864
Product Code: VX864
Other descriptive name: VX-864
Product Name: VX864
Product Code: VX864
Other descriptive name: VX-864
Vertex Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2United States;Canada;Ireland;Netherlands;Germany;United Kingdom;Sweden
4EUCTR2019-004881-16-SE
(EUCTR)
11/09/202014/07/2020Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ GenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-864 in PiZZ Subjects Alpha 1 antitrypsin deficiency in Subjects With the PiZZ Genotype
MedDRA version: 23.0;Level: PT;Classification code 10083869;Term: Alpha-1 antitrypsin deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Product Name: VX864
Product Code: VX864
INN or Proposed INN: VX-864
Other descriptive name: VX-864
Product Name: VX864
Product Code: VX864
INN or Proposed INN: VX-864
Other descriptive name: VX-864
Product Name: VX864
Product Code: VX864
INN or Proposed INN: VX-864
Other descriptive name: VX-864
Vertex Pharmaceuticals IncorporatedNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 2United States;Canada;Ireland;Netherlands;Germany;United Kingdom;Sweden